TrialCellular oncology (Dordrecht, Netherlands)2019

Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial.

Stéphanie Zunder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.